Exenatide is used clinically for the treatment of type 2 diabetes mellitus in patients whose blood glucose levels are not adequately controlled by metformin, sulfonylureas, or a combination of both. It functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the physiological actions of endogenous GLP-1 by promoting glucose-dependent insulin secretion, suppressing inappropriate glucagon secretion, slowing gastric emptying, and enhancing insulin sensitivity in peripheral tissues. Exendin-4 activates the GLP-1 receptor, thereby increasing intracellular cAMP levels in pancreatic acinar cells, without affecting VIP receptors.